Clinical Trial Update: A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy [Phase 3]

View source ↗

Summary

Ongoing Phase 3 trial of mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• CAMZYOS (MAVACAMTEN)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Cardiomyopathy, Hypertrophic | Phase 3 | Status: ACTIVE_NOT_RECRUITING